AXSOME THERAPEUTICS INC financial statements, including revenue, expenses, profit, and loss
The total revenue of 19X for the last quarter is 81.38 M EUR, and it's 17.08% higher compared to the previous quarter. The net income of Q2 24 is -74.08 M EUR.